<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00779389</url>
  </required_header>
  <id_info>
    <org_study_id>07-124</org_study_id>
    <nct_id>NCT00779389</nct_id>
  </id_info>
  <brief_title>Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family</brief_title>
  <official_title>Comparison of Biomarker Modulation by Inhibition of EGFR and/or Src Family Kinases Using Erlotinib and Dasatinib in Head and Neck Lung Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The central hypothesis to be tested in this study is that dual blockade of EGFR and Src&#xD;
      pathways or proteins are distinct compared to inhibition of either kinase alone in head and&#xD;
      neck and lung cancers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background Head and neck squamous cell carcinoma (HNSCC) constitutes 3% of all malignancies&#xD;
      and is the sixth most common malignancy worldwide. There will be an estimated 40,000 new&#xD;
      cases and 11,000 deaths in the United States in 2007 and approximately 500,000 cases&#xD;
      worldwide yearly [1]. Squamous cell carcinoma accounts for at least 90% of all head and neck&#xD;
      cancers. Surgical resection remains a standard treatment for patients with resectable HNSCC.&#xD;
      For patients with high risk of local or distant relapse, radiation therapy (RT) alone, or in&#xD;
      combination with chemotherapy, is given after surgery to improve loco-regional control and&#xD;
      overall survival. Moreover, surgery often represents the only curative option in patients who&#xD;
      relapse locoregionally. Non-small cell lung cancer (NSCLC) is the leading cause of death&#xD;
      worldwide. NSCLC is infrequently diagnosed when the cancer can be eradicated with surgical&#xD;
      extirpation.&#xD;
&#xD;
      Specific Aims&#xD;
&#xD;
        -  To determine the modulation of biomarkers by EGFR and/or Src targeting in head and neck&#xD;
           and lung cancers.&#xD;
&#xD;
        -  To determine if biomarker modulation is associated with reduction of tumor volume and/or&#xD;
           evidence of histologic response in the tumor (e.g. decreased proliferation and/or&#xD;
           decreased apoptosis) as well as safety and tolerability.&#xD;
&#xD;
      Subject population Patients will be accrued from head and neck and lung cancer patients who&#xD;
      are surgical candidates. Surgery will be the primary curative treatment for patients enrolled&#xD;
      in this study. Patients should not require any standard induction treatment prior to surgery.&#xD;
      Surgery will have to be the best treatment option as determined by the treating physician.&#xD;
      Therefore, we will not be delaying chemoradiotherapy or other curative treatment. We plan to&#xD;
      include any stage of HNSCC or NSCLC that will be managed by primary surgery. If surgery is&#xD;
      unexpectedly cancelled, the patient will be removed from the study unless there is an&#xD;
      accessible lesion for biopsy. Ideally, the pre-treatment biopsy and the intraoperative sample&#xD;
      will be obtained from the same site (when there are multiple lesions). Please see Section 3.0&#xD;
      for detailed eligibility criteria.&#xD;
&#xD;
      Treatment Plan The study drug or placebo will be taken for 14-21 days, and will be&#xD;
      discontinued one day prior to planned surgical resection. If surgery is delayed, the study&#xD;
      drug or placebo will be continued until one day prior to surgery, for up to a maximum of 28&#xD;
      days. Seven days is the minimum treatment for the patients to be evaluated. The interval&#xD;
      between the last dose of experimental drug and surgery will be 12-36 hours. Please see&#xD;
      Section 5.0 for treatment plan details. If the combination of erlotinib and dasatinib results&#xD;
      in toxicity leading to a delay in surgery, the study will be terminated.&#xD;
&#xD;
      Statistical design and sample size This is a 4-arm randomized trial that is intended to&#xD;
      estimate the effects of short-term preoperative therapy with EGFR and Src inhibitors upon a&#xD;
      panel of biomarkers. The 4 treatment arms are erlotinib, dasatinib, their combination, and a&#xD;
      placebo. We anticipate accruing 56 evaluable patients (14 patients per arm).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoints are comprised of a panel of tumor proteins to be obtained before after administration of the study drugs.</measure>
    <time_frame>2-3 week preoperative period of drug administration</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib 150 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dasatinib + placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib (150 mg) plus Dasatinib (100 mg) for 14-21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 14-21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Erlotinib 150mg will be taken once a day for 14-21days.</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib + Placebo</intervention_name>
    <description>Dasatinib (100 mg) once a day for 14-21 days.</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Sprycel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib plus Dasatinib</intervention_name>
    <description>Erlotinib (150 mg PO qD) plus Dasatinib (100 mg PO qD) 14-21 days</description>
    <arm_group_label>Arm C</arm_group_label>
    <other_name>Tarceva and Sprycel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for 14-21 days.</description>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Erlotinib 150 mg for 14-21 days.</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed, head and neck or lung cancers&#xD;
&#xD;
          -  Any NSCLC histology is eligible. Stages I, II, IIIA (T3N1 only) or recurrent NSCLC&#xD;
             that will be managed with surgery are eligible.&#xD;
&#xD;
          -  Primary tumors of any head and neck (oral cavity, oropharynx, hypopharynx, or larynx)&#xD;
             or lung site will be included.&#xD;
&#xD;
          -  Surgical resection of head and neck or lung must be planned, either as primary&#xD;
             treatment or salvage. Patients must have tissue available prior to receiving drug(s).&#xD;
&#xD;
          -  Age greater then 18 years.&#xD;
&#xD;
          -  ECOG performance status 0-2.&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must have:&#xD;
&#xD;
               1. A negative serum or urine pregnancy test within 72 hours prior to the start of&#xD;
                  study drug administration&#xD;
&#xD;
               2. Persons of reproductive potential must agree to use and utilize an adequate&#xD;
                  method of contraception throughout treatment and for at least 4 weeks after study&#xD;
                  drug is stopped.&#xD;
&#xD;
               3. Ability to take oral medication (dasatinib must be swallowed whole).&#xD;
&#xD;
               4. Concomitant Medications&#xD;
&#xD;
          -  Patients agrees to discontinue St. Johns Wort while receiving dasatinib therapy&#xD;
             (discontinue St. Johns Wort at least 5 days before starting dasatinib).&#xD;
&#xD;
          -  Patient agrees that IV biphosphonates will be withheld for the first 8 weeks of&#xD;
             dasatinib therapy due to risk of hypocalcemia.&#xD;
&#xD;
          -  Adequate hematologic, renal and hepatic function.&#xD;
&#xD;
          -  Have signed written informed consent including a HIPPA form according to institutional&#xD;
             guidelines.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who fail to meet the above criteria.&#xD;
&#xD;
          -  Prior therapy for head and neck or lung cancers is allowed, with the exception of EGFR&#xD;
             inhibitors. Any systemic therapy should have been completed at least 30 days prior to&#xD;
             study enrollment.&#xD;
&#xD;
          -  Pregnancy or breastfeeding. Women (patients or partners of male patients) of&#xD;
             childbearing potential (WOCBP) must practice acceptable methods of birth control to&#xD;
             prevent pregnancy.&#xD;
&#xD;
          -  Any unresolved chronic toxicity grade greater or equal to 2 from previous anticancer&#xD;
             therapy (except alopecia and anemia).&#xD;
&#xD;
          -  Acute hepatitis, known HIV, or active uncontrolled infection.&#xD;
&#xD;
          -  Treatment with a non-approved or investigational drug within 30 days prior to Day 1 of&#xD;
             study treatment.&#xD;
&#xD;
          -  Prior treatment with an EGFR inhibitor (tyrosine kinase inhibitor).&#xD;
&#xD;
          -  Cardiac Symptoms; any of the following should be considered for exclusion:&#xD;
&#xD;
               1. History of thromboembolic event or other condition currently requiring&#xD;
                  anticoagulation with warfarin (Coumadin). Patients whose therapy is changed to&#xD;
                  heparin is eligible.&#xD;
&#xD;
               2. History of any other cancer except basal cell carcinoma of the skin.&#xD;
&#xD;
               3. Concurrent medical condition which may increase the risk of toxicity, including:&#xD;
&#xD;
                  * Pleural or pericardial effusion of any grade&#xD;
&#xD;
               4. History of significant bleeding disorder unrelated to cancer, including:&#xD;
&#xD;
                    -  Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease).&#xD;
&#xD;
                    -  Diagnosed acquired bleeding disorder within one year (e.g., acquired&#xD;
                       anti-factor VIII antibodies).&#xD;
&#xD;
                    -  Ongoing or recent (â‰¤ 3 months) significant gastrointestinal bleeding.&#xD;
&#xD;
               5. Concomitant Medications, any of the following should be considered for exclusion:&#xD;
&#xD;
                  * Category I drugs that are generally accepted to have a risk of causing Torsades&#xD;
                  de Pointes including: (Patients must discontinue drug 7 days prior to starting&#xD;
                  dasatinib)&#xD;
&#xD;
               6. Women who:&#xD;
&#xD;
                    -  are unwilling or unable to use an acceptable method to avoid pregnancy for&#xD;
                       the entire study period and for at least 4 weeks after cessation of study&#xD;
                       drug,&#xD;
&#xD;
                    -  have a positive pregnancy test at baseline, or&#xD;
&#xD;
                    -  are pregnant or breastfeeding.&#xD;
&#xD;
               7. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated)&#xD;
                  for treatment of either a psychiatric or physical (e.g., infectious) illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer R Grandis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>October 22, 2008</study_first_submitted>
  <study_first_submitted_qc>October 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2008</study_first_posted>
  <last_update_submitted>January 12, 2016</last_update_submitted>
  <last_update_submitted_qc>January 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and Neck cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

